Table 3.
Type of Study | Type of Solution | Reported Effects | References |
---|---|---|---|
Clinical (Intravenous infusion) |
Lactated Ringer’s solution | Lower incidence of hyperchloremic acidosis * | [21,23,32] |
Lower incidence of renal dysfunction * | [31,32] | ||
Lower C-reactive protein levels * | [30] | ||
Clinical (Intravenous infusion) |
Plasma-Lyte A | Lower incidence of hyperchloremic acidosis * | [24,32] |
Lower incidence of renal dysfunction * | [24,31,32] | ||
Clinical (Peritoneal lavage) |
Povidone-iodine | Lower incidence of infectious complications * | [76] |
Pre-clinical (Peritoneal lavage) |
Lactated Ringer’s solution | No decrease in pH | [33] |
Reduced degree of mesothelial cell exfoliation * | [33] | ||
Pre-clinical (Peritoneal lavage) |
Povidone-iodine | Formation of peritoneal adhesions | [35] |
Compromises integrity of intestinal mucosa barrier | [77] | ||
In vitro | Lactated Ringer’s solution | Reduced loss of mesothelial cell adhesion * | [33] |
Povidone-iodine | Toxic to epithelial, endothelial and mesothelial cells | [78] | |
Peritoneal dialysis solution | Loss of mesothelial cell membrane integrity | [79] |
* As compared to normal saline.